Jazz Pharmaceuticals

The maker of the narcolepsy medicine Xyrem rose on its deal to buy EUSA Pharma Inc. for $650 million to diversify its drug holdings, including a therapy for leukemia. Acquiring closely held EUSA, based in Langhorne, Pa., will immediately add to earnings, Dublin-based Jazz said, and increase 2013 revenue by $210 million to $230 million. EUSA posted first-quarter net sales of $46 million.